Hormonal
Central nervous system regulation, particularly via the hypothalamus, is essential for homeostatic control of energy balance and glucose metabolism; defective brain-peripheral crosstalk contributes to obesity and type 2 diabetes.
Understanding that your brain plays a central role in regulating hunger, energy use, and blood sugar is key. If you struggle with obesity or diabetes, it may not just be about what you eat, but how your brain processes metabolic signals. Addressing central resistance (e.g., through lifestyle changes that improve brain insulin/leptin sensitivity) is as important as peripheral factors.
Accumulated evidence from genetic animal models suggests that the brain, particularly the hypothalamus, has a key role in the homeostatic regulation of energy and glucose metabolism... Defective crosstalk between the brain and peripheral organs contributes to the development of obesity and type 2 diabetes.
Why this rating
Based on a comprehensive review of genetic animal models and human clinical observations.
Source
Emerging role of the brain in the homeostatic regulation of energy and glucose metabolism
Eun Roh et al. · Experimental & Molecular Medicine · 2016
DOI 10.1038/emm.2016.4
More from this paper
- Leptin resistance in obesity involves impaired transport across the blood-brain barrier and defective hypothalamic signaling (e.g., STAT3, PI3K), leading to reduced satiety and energy expenditure.Good
- Central insulin signaling regulates hepatic glucose production via the vagus nerve and hepatic IL-6/STAT3 pathway, independent of peripheral insulin levels.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →